CD274 and non-small cell lung carcinoma: Moreover, multiple studies confirm that highly immunosuppressive Treg subsets play a critical role in mediating ICI resistance in NSCLC patients, suggesting that targeting these Treg subsets in combination with αPD-1/PD-L1 therapy may provide a promising strategy to overcome immune resistance.